BibTex RIS Kaynak Göster

Mide Karsinomalı Hastalarda Metastazlı Lenf Nodüllerinin Oranının Prognostik Değeri

Yıl 2009, Cilt: 40 Sayı: 1, 7 - 14, 20.07.2014

Nüvit Duraker Nüvit Duraker

Anahtar Kelimeler

Mide kanseri D1 lenfadenektomi lenf nodülü sınıflandırması lenf nodülü oranı prognoz

Kaynakça

  • 1. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: SpringerVerlag; 2002: 111-118.
  • 2. Volpe CM, Koo J, Miloro SM, et al. The effect of extended lymphadenectomy on survival in patients with gastric adenocarcinoma. J Am Coll Surg 1995; 181: 56-64.
  • 3. Lewis WG, Edwards P, Barry JD, et al. D2 or not D2? The gastrectomy question. Gastric Cancer 2002; 5: 29- 34.
  • 4. Kodera Y, Schwarz R, Nakao A. Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? J Am Coll Surg 2002; 195: 855-864.
  • 5. Wu C-W, Hsiung CA, Lo S-S, et al. Nodal dissection for patients with gastric cancer: a randomized controlled trial. Lancet Oncol 2006; 7: 309-315.
  • 6. Wanebo HJ, Kennedy BJ, Winchester DP, et al. Gastric carcinoma: does lymph node dissection alter survival? J Am Coll Surg 1996; 183: 616-624.
  • 7. Cuschieri A, Fayers P, Fielding J, et al for the Surgical Cooperative Group. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial. Lancet 1996; 347: 995-999.
  • 8. Hartgrink HH, van de Velde CJH, Putter H, et al. Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch Gastric Cancer Group trial. J Clin Oncol 2004; 22: 2069-2077.
  • 9. Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Ann Surg 2000; 232: 362-371.
  • 10. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Commitee on Cancer Staging, Proximal Disease, and the “Different Disease” Hypothesis. Cancer 2000; 88: 921-932.
  • 11. Mullaney PJ, Wadley MS, Hyde C, et al. Appraisal of compliance with the UICC/AJCC staging system in the staging of gastric cancer. Br J Surg 2002; 89: 1405- 1408.
  • 12. Bouvier A-M, Haas O, Piard F, et al. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer 2002; 94: 2862-2866.
  • 13. Dicken BJ, Bigam DL, Cass C, et al. Gasric adenocarcinoma: Review and considerations for future directions. Am Surg 2005; 241: 27-39.
  • 14. Kim J-P, Lee J-H, Kim S-J, et al. Clinicopathologic characteristics and prognostic factors in 10783 patients with gastric cancer. Gastric Cancer 1998; 1: 125-133.
  • 15. Takagane A, Terashima M, Abe K, et al. Evaluation of the ratio of lymph node metastasis as a prognostic factor in patients with gastric cancer. Gastric Cancer 1999; 2: 122-128.
  • 16. Inoue K, Nakane Y, Liyama H, et al. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol 2002; 9: 27-34.
  • 17. Hyung WJ, Noh SH, Yoo CH, et al. Prognostic significance of metastatic lymph node ratio in T3 gastric cancer. World J Surg 2002; 26: 323-329.
  • 18. Dhar DK, Kubota H, Tachibana M, et al. Long-term survival of transmural advanced gastric carcinoma following curative resection: multivariate analysis of prognostic factors. World J Surg 2000; 24: 588-594.
  • 19. Bando E, Yonemura Y, Taniguchi K, et al. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann Surg Oncol 2002; 9: 775-784.
  • 20. Nitti D, Marchet A, Olivieri M, et al. Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience. Ann Surg Oncol 2003; 10: 1077-1085.
  • 21. Santiago JMR, Munoz E, Marti M, et al. Metastatic lymph node ratio as a prognostic factor in gastric cancer. Eur J Surg Oncol 2005; 31: 59-66.
  • 22. Celen D,Y›ld›r›m E, Berbero¤lu U. Prognostic impact of positive lymph node ratio in gastric carcinoma. J Surg Oncol 2007; 96: 95-101.
  • 23. Marchet A, Mocellin S, Ambrosi A, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: Results from an Italian multicentric study in 1853 patients. Ann Surg 2007; 245: 543-552.
  • 24. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma -2nd English edition-. Gastric Cancer 1998; 1: 10-24.
  • 25. Siewert JR, Böttcher K, Stein HJ, Roder JD and the German Gastric Carcinoma Study Group. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449-461.
  • 26. Okura T, Nakane Y, Boku T, et al. Quantitative analysis of nodal involvement with respect to survival rate after curative gastrectomy for carcinoma. Surg Gynecol Obstet 1990; 170: 488-494.
  • 27. Saito H, Fukumoto Y, Osaki T, et al. Prognostic significance of the ratio between metastatic and dissected lymph nodes (n ratio) in patients with advanced gastric cancer. J Surg Oncol 2008; 97: 132-135.

Yıl 2009, Cilt: 40 Sayı: 1, 7 - 14, 20.07.2014

Nüvit Duraker Nüvit Duraker

Kaynakça

  • 1. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: SpringerVerlag; 2002: 111-118.
  • 2. Volpe CM, Koo J, Miloro SM, et al. The effect of extended lymphadenectomy on survival in patients with gastric adenocarcinoma. J Am Coll Surg 1995; 181: 56-64.
  • 3. Lewis WG, Edwards P, Barry JD, et al. D2 or not D2? The gastrectomy question. Gastric Cancer 2002; 5: 29- 34.
  • 4. Kodera Y, Schwarz R, Nakao A. Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? J Am Coll Surg 2002; 195: 855-864.
  • 5. Wu C-W, Hsiung CA, Lo S-S, et al. Nodal dissection for patients with gastric cancer: a randomized controlled trial. Lancet Oncol 2006; 7: 309-315.
  • 6. Wanebo HJ, Kennedy BJ, Winchester DP, et al. Gastric carcinoma: does lymph node dissection alter survival? J Am Coll Surg 1996; 183: 616-624.
  • 7. Cuschieri A, Fayers P, Fielding J, et al for the Surgical Cooperative Group. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial. Lancet 1996; 347: 995-999.
  • 8. Hartgrink HH, van de Velde CJH, Putter H, et al. Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch Gastric Cancer Group trial. J Clin Oncol 2004; 22: 2069-2077.
  • 9. Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Ann Surg 2000; 232: 362-371.
  • 10. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Commitee on Cancer Staging, Proximal Disease, and the “Different Disease” Hypothesis. Cancer 2000; 88: 921-932.
  • 11. Mullaney PJ, Wadley MS, Hyde C, et al. Appraisal of compliance with the UICC/AJCC staging system in the staging of gastric cancer. Br J Surg 2002; 89: 1405- 1408.
  • 12. Bouvier A-M, Haas O, Piard F, et al. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer 2002; 94: 2862-2866.
  • 13. Dicken BJ, Bigam DL, Cass C, et al. Gasric adenocarcinoma: Review and considerations for future directions. Am Surg 2005; 241: 27-39.
  • 14. Kim J-P, Lee J-H, Kim S-J, et al. Clinicopathologic characteristics and prognostic factors in 10783 patients with gastric cancer. Gastric Cancer 1998; 1: 125-133.
  • 15. Takagane A, Terashima M, Abe K, et al. Evaluation of the ratio of lymph node metastasis as a prognostic factor in patients with gastric cancer. Gastric Cancer 1999; 2: 122-128.
  • 16. Inoue K, Nakane Y, Liyama H, et al. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol 2002; 9: 27-34.
  • 17. Hyung WJ, Noh SH, Yoo CH, et al. Prognostic significance of metastatic lymph node ratio in T3 gastric cancer. World J Surg 2002; 26: 323-329.
  • 18. Dhar DK, Kubota H, Tachibana M, et al. Long-term survival of transmural advanced gastric carcinoma following curative resection: multivariate analysis of prognostic factors. World J Surg 2000; 24: 588-594.
  • 19. Bando E, Yonemura Y, Taniguchi K, et al. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann Surg Oncol 2002; 9: 775-784.
  • 20. Nitti D, Marchet A, Olivieri M, et al. Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience. Ann Surg Oncol 2003; 10: 1077-1085.
  • 21. Santiago JMR, Munoz E, Marti M, et al. Metastatic lymph node ratio as a prognostic factor in gastric cancer. Eur J Surg Oncol 2005; 31: 59-66.
  • 22. Celen D,Y›ld›r›m E, Berbero¤lu U. Prognostic impact of positive lymph node ratio in gastric carcinoma. J Surg Oncol 2007; 96: 95-101.
  • 23. Marchet A, Mocellin S, Ambrosi A, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: Results from an Italian multicentric study in 1853 patients. Ann Surg 2007; 245: 543-552.
  • 24. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma -2nd English edition-. Gastric Cancer 1998; 1: 10-24.
  • 25. Siewert JR, Böttcher K, Stein HJ, Roder JD and the German Gastric Carcinoma Study Group. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449-461.
  • 26. Okura T, Nakane Y, Boku T, et al. Quantitative analysis of nodal involvement with respect to survival rate after curative gastrectomy for carcinoma. Surg Gynecol Obstet 1990; 170: 488-494.
  • 27. Saito H, Fukumoto Y, Osaki T, et al. Prognostic significance of the ratio between metastatic and dissected lymph nodes (n ratio) in patients with advanced gastric cancer. J Surg Oncol 2008; 97: 132-135.
Toplam 27 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Araştırmalar
Yazarlar

Nüvit Duraker Bu kişi benim

Nüvit Duraker Bu kişi benim

Yayımlanma Tarihi 20 Temmuz 2014
Yayımlandığı Sayı Yıl 2009 Cilt: 40 Sayı: 1

Kaynak Göster

APA Duraker, N., & Duraker, N. (2014). Mide Karsinomalı Hastalarda Metastazlı Lenf Nodüllerinin Oranının Prognostik Değeri. Cerrahpaşa Tıp Dergisi, 40(1), 7-14.
AMA Duraker N, Duraker N. Mide Karsinomalı Hastalarda Metastazlı Lenf Nodüllerinin Oranının Prognostik Değeri. Cerrahpaşa Tıp Dergisi. Temmuz 2014;40(1):7-14.
Chicago Duraker, Nüvit, ve Nüvit Duraker. “Mide Karsinomalı Hastalarda Metastazlı Lenf Nodüllerinin Oranının Prognostik Değeri”. Cerrahpaşa Tıp Dergisi 40, sy. 1 (Temmuz 2014): 7-14.
EndNote Duraker N, Duraker N (01 Temmuz 2014) Mide Karsinomalı Hastalarda Metastazlı Lenf Nodüllerinin Oranının Prognostik Değeri. Cerrahpaşa Tıp Dergisi 40 1 7–14.
IEEE N. Duraker ve N. Duraker, “Mide Karsinomalı Hastalarda Metastazlı Lenf Nodüllerinin Oranının Prognostik Değeri”, Cerrahpaşa Tıp Dergisi, c. 40, sy. 1, ss. 7–14, 2014.
ISNAD Duraker, Nüvit - Duraker, Nüvit. “Mide Karsinomalı Hastalarda Metastazlı Lenf Nodüllerinin Oranının Prognostik Değeri”. Cerrahpaşa Tıp Dergisi 40/1 (Temmuz 2014), 7-14.
JAMA Duraker N, Duraker N. Mide Karsinomalı Hastalarda Metastazlı Lenf Nodüllerinin Oranının Prognostik Değeri. Cerrahpaşa Tıp Dergisi. 2014;40:7–14.
MLA Duraker, Nüvit ve Nüvit Duraker. “Mide Karsinomalı Hastalarda Metastazlı Lenf Nodüllerinin Oranının Prognostik Değeri”. Cerrahpaşa Tıp Dergisi, c. 40, sy. 1, 2014, ss. 7-14.
Vancouver Duraker N, Duraker N. Mide Karsinomalı Hastalarda Metastazlı Lenf Nodüllerinin Oranının Prognostik Değeri. Cerrahpaşa Tıp Dergisi. 2014;40(1):7-14.